Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARISMA: Cipargamin in Severe Malaria
NCT04675931Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of cipargamin in malaria (3 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum at 12 hours. Started Mar 2022; status: completed.
02
Drugs
cipargamin
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04675931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675931.